News & Updates
Filter by Specialty:
Very low-calorie ketogenic diet plus omega-3 promotes weight loss in class I obesity
For individuals with class I obesity, a very low-calorie ketogenic diet (VLCKD) with omega-3 supplementation results in fat mass reduction while preserving fat-free mass (FFM), as shown in a study. Furthermore, there are improvements seen in satiety hormones, such as higher ghrelin and lower leptin, and in the metabolic profiles.
Very low-calorie ketogenic diet plus omega-3 promotes weight loss in class I obesity
25 Jan 2022Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
The risk stratification criteria used in the CHAARTED and LATITUDE trials can accurately assess prognosis in patients with castration-resistant prostate cancer (CRPC), but are insufficient to differentiate between the therapeutic outcomes of androgen receptor pathway inhibitors (ARPI) and docetaxel, a new study has found.
Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
24 Jan 2022Esaxerenone produces favourable night-time BP-lowering effect in Asians
The novel highly selective mineralocorticoid receptor blocker esaxerenone holds promise in the treatment of nocturnal hypertension, yielding substantial reductions in night-time blood pressure (BP), especially in Japanese patients with a riser pattern, as well as in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, according to a post hoc analysis of a phase III study.
Esaxerenone produces favourable night-time BP-lowering effect in Asians
24 Jan 2022Peak exercise SBP below predicted value tied to future CVD, mortality
A peak systolic blood pressure (SBP) at clinical exercise testing that is slightly lower than the predicted value appears predictive of future cardiovascular disease (CVD) and mortality, suggests a study. Higher peak SBP, however, is not associated with such risks.
Peak exercise SBP below predicted value tied to future CVD, mortality
24 Jan 2022KEEPsAKE findings boost risankizumab efficacy, safety for PsA
In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
24 Jan 2022PSA mRNA in circulating tumour cells a potential new biomarker for prostate cancer progression
Levels of prostate specific antigen (PSA) mRNA in circulating tumour cells can be used alongside serum PSA protein levels to refine the assessment of disease progression in patient with metastatic castration-resistant prostate cancer (mCRPC), a new study has found.
PSA mRNA in circulating tumour cells a potential new biomarker for prostate cancer progression
23 Jan 2022Hypothyroidism not associated with worse prognosis in COVID-19
Patients with hypothyroidism who develop COVID-19 have a lower mechanical ventilation requirement and are less likely to die in the hospital, as reported in a study.